Pancreatic Cancer Research

ResearcherKanazawa UniversityActive in the last 2 years

Hidehiro Tajima

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1605-9747; OpenAlex author ID A5056226936. Sources: OpenAlex.

Their work

Papers
22 (first author 7, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 4 papers · 2014: 3 papers · 2015: none · 2016: none · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 22

  1. Investigation of CRP and NLR as potential biomarkers for redefining biological borderline resectable pancreatic cancer. First author DOI 10.3892/ol.2026.15783↗
  2. Needle tract seeding after fine-needle aspiration for pancreatic cancer assessed by endoscopy and endoscopic ultrasound. Co-author DOI 10.1055/a-2738-7245↗
  3. Verification of Resectability Status for Pancreatic Cancer: Radiological and Pathological Analysis of Patients Undergoing Pancreatoduodenectomy With Combined R… First author DOI 10.1097/mpa.0000000000001964↗
  4. A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nab-paclitaxel for resectable pancreatic cancer. Co-author DOI 10.3892/mco.2020.2188↗
  5. [Intestinal Care Using L‒Glutamine Supplement and Probiotics Can Induce a Strong Anti‒Tumor Immune Response through the Induction of Mature Tertiary Lymphoid S… Last author PMID 33976027↗
  6. Impact of Extravasated Platelet Activation and Podoplanin-positive Cancer-associated Fibroblasts in Pancreatic Cancer Stroma. First author DOI 10.21873/anticanres.13750↗
  7. Contribution of equilibrative nucleoside transporters 1 and 2 to gemcitabine uptake in pancreatic cancer cells. Co-author DOI 10.1002/bdd.2131↗
  8. Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer. Co-author DOI 10.3892/mco.2018.1579↗
  9. [A Case of Pathological Complete Response Induced by Preoperative Chemotherapy with Gemcitabine plus Nab-Paclitaxel in a Patient with Pancreatic Cancer on Hemo… First author PMID 30692318↗
  10. Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreat… Co-author DOI 10.1007/s10238-015-0394-x↗
  11. Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives. Co-author DOI 10.3892/ol.2017.6008↗
  12. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Soc… Co-author DOI 10.1002/jhbp.15↗
  13. Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells. Co-author DOI 10.3892/ol.2014.2553↗
  14. [A case report of hepatic arterial infusion chemotherapy and RFA for liver metastasis from pancreatic cancer]. First author PMID 25731471↗
  15. A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer. Co-author DOI 10.3892/mco.2013.133↗
  16. Hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil or oral S-1 improves the prognosis of patients with postoperative liver metastases f… Co-author DOI 10.3892/mco.2013.152↗
  17. [Gemcitabine augments major histocompatibility complex class I-related chain A expression in pancreatic cancer]. First author PMID 24393861↗
  18. [Hepatic arterial infusion chemotherapy with gemcitabine for patients with postoperative liver metastases from pancreatic cancer]. Co-author PMID 24393883↗
  19. Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer. Co-author DOI 10.3892/etm.2012.482↗
  20. Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44. Co-author DOI 10.3892/ol.2012.657↗
  21. Increased E-selectin in hepatic ischemia-reperfusion injury mediates liver metastasis of pancreatic cancer. First author DOI 10.3892/or.2012.1896↗
  22. Pilot study of hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for patients with postoperative liver metastases from pancreatic canc… Co-author DOI 10.3892/etm.2011.190↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tetsuo Ohta · 19 shared papers, 2011–2022 · strength 1.09
  2. Isamu Makino · 17 shared papers, 2011–2022 · strength 0.98
  3. Tomoharu Miyashita · 12 shared papers, 2013–2021 · strength 0.76
  4. Hideyuki Yoshitomi · 2 shared papers, 2025–2026 · strength 0.62
  5. Itasu Ninomiya · 12 shared papers, 2011–2022 · strength 0.61
  6. Mitsuyoshi Okazaki · 6 shared papers, 2018–2022 · strength 0.60
  7. Keishi Kawasaki · 1 shared paper, 2026 · strength 0.33
  8. Masaya Tamano · 1 shared paper, 2025 · strength 0.28
  9. Koichi Soga · 1 shared paper, 2025 · strength 0.28
  10. Yoshimichi Sai · 3 shared papers, 2013–2018 · strength 0.12
  11. Toshifumi Gabata · 3 shared papers, 2011–2013 · strength 0.07
  12. Takuya Shimada · 1 shared paper, 2018 · strength 0.07
  13. Masato Hioki · 1 shared paper, 2018 · strength 0.07
  14. Ikumi Tamai · 1 shared paper, 2018 · strength 0.07
  15. S Kitamura · 2 shared papers, 2012 · strength 0.05
  16. Osamu Matsui · 2 shared papers, 2011–2013 · strength 0.04
  17. Keisuke Yamazaki · 1 shared paper, 2014 · strength 0.04
  18. Akira Nakayama · 1 shared paper, 2014 · strength 0.04
  19. Tomoo Kosuge · 1 shared paper, 2014 · strength 0.03
  20. Keita Wada · 1 shared paper, 2014 · strength 0.03
  21. Takaho Okada · 1 shared paper, 2014 · strength 0.03
  22. Hiroyuki Shinchi · 1 shared paper, 2014 · strength 0.03
  23. Yoshiaki Murakami · 1 shared paper, 2014 · strength 0.03
  24. Sohei Satoi · 1 shared paper, 2014 · strength 0.03
  25. Hideo Baba · 1 shared paper, 2014 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.